Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Rating of “Reduce” by Analysts

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have received a consensus recommendation of “Reduce” from the nine analysts that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $2.4714.

DH has been the subject of several analyst reports. Wall Street Zen upgraded Definitive Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Bank of America reiterated an “underperform” rating and issued a $0.70 price target on shares of Definitive Healthcare in a research note on Monday, June 29th. Zacks Research raised shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Robert W. Baird set a $1.10 price objective on shares of Definitive Healthcare in a research note on Friday, May 8th. Finally, Barclays decreased their target price on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a report on Monday, March 30th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of DH. BNP Paribas Financial Markets increased its holdings in Definitive Healthcare by 32.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock worth $72,000 after buying an additional 4,407 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in Definitive Healthcare by 109.3% during the 4th quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock valued at $32,000 after acquiring an additional 5,970 shares during the period. Invesco Ltd. lifted its stake in Definitive Healthcare by 5.8% during the 4th quarter. Invesco Ltd. now owns 117,427 shares of the company’s stock valued at $337,000 after acquiring an additional 6,400 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Definitive Healthcare during the 2nd quarter valued at about $32,000. Finally, Creative Planning boosted its holdings in shares of Definitive Healthcare by 41.7% during the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock valued at $112,000 after acquiring an additional 8,428 shares during the last quarter. 98.67% of the stock is owned by institutional investors.

Definitive Healthcare Stock Up 4.8%

Shares of DH stock traded up $0.04 during trading hours on Thursday, hitting $0.90. 49,801 shares of the company’s stock traded hands, compared to its average volume of 385,098. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.81. The stock’s fifty day simple moving average is $0.86 and its two-hundred day simple moving average is $1.42. Definitive Healthcare has a 12-month low of $0.62 and a 12-month high of $4.70. The stock has a market cap of $95.28 million, a price-to-earnings ratio of -0.56, a PEG ratio of 10.49 and a beta of 1.33.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. The company had revenue of $55.93 million for the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. On average, analysts expect that Definitive Healthcare will post 0.05 EPS for the current year.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.